# E2814

Source: https://onco.cc/drugs/da-e2814/  
OnCo record `da-e2814` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

E2814 is an investigational anti-tau antibody. It is not approved for dementia and is available only in research settings.

## Summary

Eisai’s tau programme is listed so the atlas is not amyloid-only. Benefit and safety remain trial questions. A registry listing is not a recommendation to enrol.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Modality: mAb
- Mechanism: Investigational antibody directed at microtubule-binding-region tau.

## Sources

- ClinicalTrials.gov NCT04971733: https://clinicaltrials.gov/study/NCT04971733

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- targets: [Tau](https://onco.cc/targets/da-target-tau/)
- companies: [Eisai](https://onco.cc/companies/da-eisai/)
- trials: [E2814 tau antibody (DIAD)](https://onco.cc/trials/da-trial-e2814/)
- technologies: [Tau-directed therapeutics](https://onco.cc/technologies/da-tech-tau-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/da-e2814.json